Sun Pharma Advanced Research Co Ltd
SPARCSun Pharma Advanced Research Co Ltd
SPARCPrice Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
AvgThe stock is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
-17.31 | 56.26 | — |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
51.92 | 6.65 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Sun Pharma Advanced Research Company Limited is engaged in the research and experimental development on natural sciences and engineering (Pharmacy).
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Mankind Pharma Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Revenue Forecast
Earnings Per Share Forecast
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2023 | FY 2024 | TTM | |||
---|---|---|---|---|---|---|
Total Revenue | 249.66 | 105.02 | 72.48 | |||
Raw Materials | 0.00 | 0.00 | 464.81 | |||
Power & Fuel Cost | 5.75 | 6.14 | ||||
Employee Cost | 107.00 | 141.84 | ||||
Selling & Administrative Expenses | 289.71 | 267.06 | ||||
Operating & Other expenses | 50.38 | 62.60 | ||||
EBITDA | -203.18 | -372.62 | -392.33 | |||
Depreciation/Amortization | 11.77 | 12.51 | 12.53 | |||
PBIT | -214.95 | -385.13 | -404.86 | |||
Interest & Other Items | 7.63 | 1.69 | 2.87 | |||
PBT | -222.58 | -386.82 | -407.73 | |||
Taxes & Other Items | 0.00 | 0.38 | 0.94 | |||
Net Income | -222.58 | -387.20 | -408.67 | |||
EPS | -6.86 | -11.93 | -12.59 | |||
DPS | 0.00 | 0.00 | 0.00 | |||
Payout ratio | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFInvestor Presentation
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Sun Pharma Advanced Research Co Ltd | -18.27 | 56.26 | — |
Sun Pharmaceutical Industries Ltd | 45.12 | 6.44 | 0.75% |
Cipla Ltd | 28.85 | 4.44 | 0.88% |
Torrent Pharmaceuticals Ltd | 69.10 | 16.69 | 0.83% |
Price Comparison
Compare SPARC with any stock or ETFShareholdings
Promoter Holdings Trend
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding Sun Pharma Advanced Research Co Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Plan Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.5214% | Percentage of the fund’s portfolio invested in the stock 0.72% | Change in the portfolio weight of the stock over the last 3 months 0.72% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 41/51 (+2) |
Nippon India Nifty Smallcap 250 Index Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0316% | Percentage of the fund’s portfolio invested in the stock 0.11% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 27/294 (-1) |
SBI Nifty Smallcap 250 Index Fund - Direct Plan - Growth Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.0192% | Percentage of the fund’s portfolio invested in the stock 0.11% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 148/294 (-9) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
SPARC has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
The LoI outlines the key terms of license and rights for development and commercialization by Tiller. Under the LoI, SPARC will receive a 55% equity stake in Tiller upon execution of the agreement. The equity will vest in two tranches: 45% upon execution of the license agreement, and the remaining 10% upon the achievement of specific milestones or within 6 months of the agreement's execution. Anil Raghavan, CEO of SPARC, said, 'We are excited about the opportunity to partner with Tiller to advance potential treatment of solid tumors affecting millions each year, with no current cure.' Sun Pharma Advanced Research Company (SPARC) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. The company reported a net loss of Rs 107.28 crore in Q2 FY25 as compared with net loss of Rs 86.08 crore in Q2 FY24. Net sales declined 39.29% year on year (YoY) to 12.86 crore in the quarter ended 30 September 2024. Shares of Sun Pharma Advanced Research Company fell 1.45% to Rs 227.15 on the BSE. Powered by Capital Market - Live
Sun Pharma Advanced Research Company announced the signing of a binding Letter of Intent (LOI) with the University of California, San Francisco (UCSF), through the office of OTMA, and Tiller Therapeutics Inc. (Tiller) to license SPARC's rights in the joint intellectual property (IP) held between SPARC and UCSF for pre-clinical oncology asset along with associated IP. The LOI outlines the key terms of license and rights for development and commercialization by Tiller. Under the terms of the LOI, SPARC will receive 55% equity stake in Tiller upon execution of LOI. The equity will vest in two tranches; 45% equity will vest upon execution of license agreement and the remaining 10% equity will vest at the earlier of achievement of certain milestones by Tiller or within 6 months of execution of license agreement. Other terms of the license will be outlined in the license agreement. Powered by Capital Market - Live
Avanti Feeds Ltd, Jubilant Pharmova Ltd, Prestige Estates Projects Ltd, Oberoi Realty Ltd are among the other stocks to see a surge in volumes on NSE today, 16 December 2024.Sun Pharma Advanced Research Company Ltd notched up volume of 152.55 lakh shares by 14:14 IST on NSE, a 41.98 fold spurt over two-week average daily volume of 3.63 lakh shares. The stock rose 12.43% to Rs.238.31. Volumes stood at 2.85 lakh shares in the last session.Avanti Feeds Ltd saw volume of 41.59 lakh shares by 14:14 IST on NSE, a 13.45 fold spurt over two-week average daily volume of 3.09 lakh shares. The stock increased 7.45% to Rs.665.95. Volumes stood at 2.33 lakh shares in the last session.Jubilant Pharmova Ltd notched up volume of 10 lakh shares by 14:14 IST on NSE, a 6.16 fold spurt over two-week average daily volume of 1.62 lakh shares. The stock slipped 1.86% to Rs.1,093.60. Volumes stood at 1.3 lakh shares in the last session.Prestige Estates Projects Ltd recorded volume of 18.13 lakh shares by 14:14 IST on NSE, a 3.69 times surge over two-week average daily volume of 4.91 lakh shares. The stock gained 4.47% to Rs.1,833.00. Volumes stood at 7.81 lakh shares in the last session.Oberoi Realty Ltd clocked volume of 30.79 lakh shares by 14:14 IST on NSE, a 3.26 times surge over two-week average daily volume of 9.43 lakh shares. The stock gained 6.90% to Rs.2,263.75. Volumes stood at 6.57 lakh shares in the last session.Powered by Capital Market - Live
Jindal Worldwide Ltd, Vakrangee Ltd, Wockhardt Ltd and Hemisphere Properties India Ltd are among the other gainers in the BSE's 'A' group today, 16 December 2024.Sun Pharma Advanced Research Company Ltd spiked 9.83% to Rs 232.9 at 11:46 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 3.07 lakh shares were traded on the counter so far as against the average daily volumes of 42206 shares in the past one month. Jindal Worldwide Ltd surged 8.71% to Rs 419.9. The stock was the second biggest gainer in 'A' group. On the BSE, 49383 shares were traded on the counter so far as against the average daily volumes of 42696 shares in the past one month. Vakrangee Ltd soared 8.53% to Rs 30.14. The stock was the third biggest gainer in 'A' group. On the BSE, 21.87 lakh shares were traded on the counter so far as against the average daily volumes of 13.16 lakh shares in the past one month. Wockhardt Ltd rose 7.59% to Rs 1502.8. The stock was the fourth biggest gainer in 'A' group. On the BSE, 1.28 lakh shares were traded on the counter so far as against the average daily volumes of 47546 shares in the past one month. Hemisphere Properties India Ltd exploded 7.40% to Rs 183.5. The stock was the fifth biggest gainer in 'A' group. On the BSE, 64624 shares were traded on the counter so far as against the average daily volumes of 46248 shares in the past one month. Powered by Capital Market - Live
Raymond Ltd, Praj Industries Ltd, Adani Green Energy Ltd, Mangalore Refinery And Petrochemicals Ltd are among the other stocks to see a surge in volumes on NSE today, 22 November 2024.Sun Pharma Advanced Research Company Ltd witnessed volume of 40.83 lakh shares by 14:14 IST on NSE, a 13.33 times surge over two-week average daily volume of 3.06 lakh shares. The stock increased 8.35% to Rs.206.23. Volumes stood at 2.59 lakh shares in the last session.Raymond Ltd recorded volume of 17.78 lakh shares by 14:14 IST on NSE, a 12.91 times surge over two-week average daily volume of 1.38 lakh shares. The stock gained 8.45% to Rs.1,547.45. Volumes stood at 1.68 lakh shares in the last session.Praj Industries Ltd notched up volume of 51.83 lakh shares by 14:14 IST on NSE, a 12.5 fold spurt over two-week average daily volume of 4.15 lakh shares. The stock rose 9.73% to Rs.741.20. Volumes stood at 3.12 lakh shares in the last session.Adani Green Energy Ltd saw volume of 168.43 lakh shares by 14:14 IST on NSE, a 8.88 fold spurt over two-week average daily volume of 18.97 lakh shares. The stock dropped 4.30% to Rs.1,096.40. Volumes stood at 95.24 lakh shares in the last session.Mangalore Refinery And Petrochemicals Ltd notched up volume of 202.28 lakh shares by 14:14 IST on NSE, a 8.26 fold spurt over two-week average daily volume of 24.50 lakh shares. The stock rose 6.57% to Rs.154.58. Volumes stood at 14.9 lakh shares in the last session.Powered by Capital Market - Live
Net sales declined 39.29% year on year (YoY) to 12.86 crore in the quarter ended 30 September 2024. Total expenses rose 3.43% YoY to Rs 120.07 crore in September 2024 quarter. Employee benefit expenses was Rs 38.48 crore (up 25.3% YoY), professional charges stood at Rs 30.75 crore (down 26.58% YoY), clinical trial expenses at Rs 25.53 crore (up 40.2% YoY). Sun Pharma Advanced Research Company (SPARC) is a pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery.Powered by Capital Market - Live
Net Loss of Sun Pharma Advanced Research Company reported to Rs 107.33 crore in the quarter ended September 2024 as against net loss of Rs 86.42 crore during the previous quarter ended September 2023. Sales declined 39.28% to Rs 12.86 crore in the quarter ended September 2024 as against Rs 21.18 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales12.8621.18 -39 OPM %-800.23-431.87 - PBDT-104.01-83.24 -25 PBT-107.17-86.42 -24 NP-107.33-86.42 -24 Powered by Capital Market - Live
Sun Pharma Advanced Research Company will hold a meeting of the Board of Directors of the Company on 4 November 2024Powered by Capital Market - Live
Sun Pharma Advanced Research Company reports consolidated net loss of Rs 95.90 crore in the June 2024 quarter
Net Loss of Sun Pharma Advanced Research Company reported to Rs 95.90 crore in the quarter ended June 2024 as against net loss of Rs 95.35 crore during the previous quarter ended June 2023. Sales declined 29.81% to Rs 16.81 crore in the quarter ended June 2024 as against Rs 23.95 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales16.8123.95 -30 OPM %-555.38-426.64 - PBDT-92.36-92.25 0 PBT-95.50-95.35 0 NP-95.90-95.35 -1 Powered by Capital Market - Live
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
High Pledged Promoter Holding
A significant proportion of promoter holdings is pledged